Neu­ro­crine flesh­es out its PhI­II case for val­be­nazine; Avro­bio adds to gene ther­a­py pipeline

Neu­ro­crine has al­ready post­ed the key late-stage da­ta that it took to the FDA in build­ing a case for In­grez­za (val­be­nazine) as a new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.